Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1024P - Baseline biomarkers associated with clinical benefit in patients with solid tumors refractory to immune checkpoint inhibitors (ICIs) treated with live biotherapeutic MRx0518 in combination with pembrolizumab

Date

16 Sep 2021

Session

ePoster Display

Topics

Staging and Imaging;  Cytotoxic Therapy;  Basic Science;  Clinical Research

Tumour Site

Presenters

Edwin Parra

Citation

Annals of Oncology (2021) 32 (suppl_5): S829-S866. 10.1016/annonc/annonc705

Authors

E.R. Parra1, M. Adriani2, C. Freitas Pinto Lima1, J. Li1, C. Haymaker1, R. Parikh3, E. Bernicker4, D. Davar5, A. Chaudhry6, A. Stevenson2, C. Badham2, G. Fyvie2, M. Chisamore7, S. Pant8

Author affiliations

  • 1 Translational Molecular Pathology, MD Anderson Cancer Center, 77030 - Houston/US
  • 2 N/a, 4D pharma plc, D pharma plc/GB
  • 3 Oncology, University of Kansas, 66205 - Westwood/US
  • 4 N/a, The Methodist Hospital Research Institute, Houston/US
  • 5 N/a, University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh/US
  • 6 N/a, Medical Oncology Summit Cancer Centers, 99208 - Spokane/US
  • 7 Oncology Early Clinical Development, Merck Sharp & Dohme Corp. USA, NJ 08889 - Whitehouse Station/US
  • 8 Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1024P

Background

MRx0518 is a novel, gut microbiome derived, single strain oral Live Biotherapeutic Product (LBP) with potent anti-tumour efficacy in multiple cancer models. MRx0518 has been shown to induce activation of CD8+ T-cells and suppress differentiation of Treg cells in vitro, and to increase the CD8/Treg cell ratio in murine models of cancer. In an ongoing phase I/II study (NCT03637803), preliminary antitumor activity has been observed in patient’s refractory to ICIs when MRx0518 is administered in combination with pembrolizumab. This clinical data has been previously reported, and here we present data from biomarker analysis indicating characteristics of patients that have responded.

Methods

Patients received MRx0518 1 capsule PO BID (1x1010 to 1x1011 CFU) and pembrolizumab (200mg Q3W) for up to 2 years or until progression. Eligible patients have experienced clinical benefit from a prior ICI before eventually progressing. Tumour response was assessed every 9 weeks by RECIST v1.1. Responders were classed as patients who experienced CR, PR or SD ≥6 months. To date, baseline FFPE tumour biopsies from 12 patients, 4 responders and 8 non responders, were immunoprofilling using a mIF panel against; CD3, CD8, PD-1, FOXP3, Ki-67, PD-L1, CD68, and cytokeratin antibodies in tumor and stroma compatments form the tissue using image analysis.

Results

Response to therapy was associated with higher baseline densities of tumour infiltrating Treg (CD3+Foxp3+) (P=0.0381) and proliferating total T-cells (CD3+Ki67+) (P=0.0048) at baseline, whereas higher densities of macrophages (CD68+ cells, P=0.0303) were detected in the stroma and tumour tissue compartment of non-responders.

Conclusions

Understanding mechanisms of resistance to ICIs is key in identifying patients who may respond to subsequent therapies. This limited analysis, together with the observations of increased CD8+ T-cell activation and reduced induction of Treg cells in the presence of tolerogenic cytokines in vitro and in preclinical models, provides insight for further investigation into the potential for MRx0518 + pembrolizumab to overcome Treg-mediated acquired resistance to ICIs.

Clinical trial identification

NCT03637803.

Editorial acknowledgement

Legal entity responsible for the study

4D Pharma PLC.

Funding

4D Pharma PLC.

Disclosure

M. Adriani: Other, Institutional, Full or part-time Employment: 4D Pharma PLC. R. Parikh: Other, Institutional, Full or part-time Employment: 4D Pharma PLC. A. Stevenson: Other, Institutional, Full or part-time Employment: 4D Pharma PLC. C. Badham: Other, Institutional, Full or part-time Employment: 4D Pharma PLC. G. Fyvie: Other, Institutional, Full or part-time Employment: 4D Pharma PLC. M. Chisamore: Other, Institutional, Full or part-time Employment: 7Merck & Co., Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.